Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.

Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, Torres Garrido B, Schulte-Mecklenbeck A, Gross CC, Breuer J, Hundehege P, Posevitz V, Pignolet B, Nebel G, Glander S, Freise N, Austermann J, Wirth T, Campbell GR, Schneider-Hohendorf T, Eveslage M, Brassat D, Schwab N, Loser K, Roth J, Busch KB, Stoll M, Mahad DJ, Meuth SG, Turner T, Bar-Or A, Wiendl H.

Sci Transl Med. 2019 May 1;11(490). pii: eaao5563. doi: 10.1126/scitranslmed.aao5563.

PMID:
31043571
2.

VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells.

Breuer J, Schneider-Hohendorf T, Ostkamp P, Herich S, Rakhade S, Antonijevic I, Klotz L, Wiendl H, Schwab N.

Int Immunol. 2019 May 21;31(6):407-412. doi: 10.1093/intimm/dxz018.

PMID:
30783682
3.

Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.

Göbel K, Asaridou CM, Merker M, Eichler S, Herrmann AM, Geuß E, Ruck T, Schüngel L, Groeneweg L, Narayanan V, Schneider-Hohendorf T, Gross CC, Wiendl H, Kehrel BE, Kleinschnitz C, Meuth SG.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):271-276. doi: 10.1073/pnas.1810020116. Epub 2018 Dec 17.

4.

Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus.

Breuer J, Korpos E, Hannocks MJ, Schneider-Hohendorf T, Song J, Zondler L, Herich S, Flanagan K, Korn T, Zarbock A, Kuhlmann T, Sorokin L, Wiendl H, Schwab N.

J Neuroinflammation. 2018 Aug 22;15(1):236. doi: 10.1186/s12974-018-1276-4.

5.

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid-Results from the ToFingo Successor Study.

Lohmann L, Janoschka C, Schulte-Mecklenbeck A, Klinsing S, Kirstein L, Hanning U, Wirth T, Schneider-Hohendorf T, Schwab N, Gross CC, Eveslage M, Meuth SG, Wiendl H, Klotz L.

Front Immunol. 2018 Jul 9;9:1560. doi: 10.3389/fimmu.2018.01560. eCollection 2018.

6.

Sex bias in MHC I-associated shaping of the adaptive immune system.

Schneider-Hohendorf T, Görlich D, Savola P, Kelkka T, Mustjoki S, Gross CC, Owens GC, Klotz L, Dornmair K, Wiendl H, Schwab N.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2168-2173. doi: 10.1073/pnas.1716146115. Epub 2018 Feb 12.

7.

Nitazoxanide May Modify the Course of Progressive Multifocal Leukoencephalopathy.

Hautala TJ, Perelygina L, Vuorinen T, Hautala NM, Hägg PM, Bode MK, Rusanen HT, Renko MH, Glumoff V, Schwab N, Schneider-Hohendorf T, Murk JL, Sullivan KE, Seppänen MRJ.

J Clin Immunol. 2018 Jan;38(1):4-6. doi: 10.1007/s10875-017-0463-x. Epub 2017 Nov 20. No abstract available.

PMID:
29159786
8.

The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.

Reuwer AQ, Heron M, van der Dussen D, Schneider-Hohendorf T, Murk JL.

Acta Neurol Scand. 2017 Nov;136 Suppl 201:37-44. doi: 10.1111/ane.12840. Review.

PMID:
29068484
9.

Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium.

Breuer J, Herich S, Schneider-Hohendorf T, Chasan AI, Wettschureck N, Gross CC, Loser K, Zarbock A, Roth J, Klotz L, Wiendl H, Schwab N.

Mult Scler. 2017 Oct 1:1352458517735189. doi: 10.1177/1352458517735189. [Epub ahead of print]

PMID:
28984166
10.

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.

Schwab N, Schneider-Hohendorf T, Hoyt T, Gross CC, Meuth SG, Klotz L, Foley JF, Wiendl H.

Mult Scler. 2018 Apr;24(5):563-573. doi: 10.1177/1352458517728814. Epub 2017 Aug 29.

PMID:
28847222
11.

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier.

Schulte-Mecklenbeck A, Bhatia U, Schneider-Hohendorf T, Schwab N, Wiendl H, Gross CC.

J Vis Exp. 2017 Apr 5;(122). doi: 10.3791/55390.

12.

Progressive multifocal leukoencephalopathy and black fungus in a patient with rheumatoid arthritis without severe lymphocytopenia.

de Regt MJ, Murk JL, Schneider-Hohendorf T, Wattjes MP, Hoepelman AI, Arends JE.

JMM Case Rep. 2016 Aug 30;3(4):e005053. doi: 10.1099/jmmcr.0.005053. eCollection 2016 Aug.

13.

Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification.

Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H.

Neurology. 2017 Mar 21;88(12):1197-1205. doi: 10.1212/WNL.0000000000003739. Epub 2017 Feb 22. Review.

PMID:
28228564
14.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
15.

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.

Schwab N, Schneider-Hohendorf T, Wiendl H.

Neurology. 2016 Aug 30;87(9):958-9. doi: 10.1212/01.wnl.0000496643.57775.41. No abstract available.

PMID:
27572431
16.

Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.

Gross CC, Schulte-Mecklenbeck A, Rünzi A, Kuhlmann T, Posevitz-Fejfár A, Schwab N, Schneider-Hohendorf T, Herich S, Held K, Konjević M, Hartwig M, Dornmair K, Hohlfeld R, Ziemssen T, Klotz L, Meuth SG, Wiendl H.

Proc Natl Acad Sci U S A. 2016 May 24;113(21):E2973-82. doi: 10.1073/pnas.1524924113. Epub 2016 May 9.

17.

CD8(+) T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing.

Schneider-Hohendorf T, Mohan H, Bien CG, Breuer J, Becker A, Görlich D, Kuhlmann T, Widman G, Herich S, Elpers C, Melzer N, Dornmair K, Kurlemann G, Wiendl H, Schwab N.

Nat Commun. 2016 Apr 4;7:11153. doi: 10.1038/ncomms11153.

18.

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values.

Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Göbel K, Brassat D, Wiendl H.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e195. doi: 10.1212/NXI.0000000000000195. eCollection 2016 Feb.

19.

CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.

Dubinski D, Wölfer J, Hasselblatt M, Schneider-Hohendorf T, Bogdahn U, Stummer W, Wiendl H, Grauer OM.

Neuro Oncol. 2016 Jun;18(6):807-18. doi: 10.1093/neuonc/nov280. Epub 2015 Nov 17.

20.

PML risk stratification using anti-JCV antibody index and L-selectin.

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H.

Mult Scler. 2016 Jul;22(8):1048-60. doi: 10.1177/1352458515607651. Epub 2015 Oct 2.

PMID:
26432858
21.

Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid.

Grauer OM, Reichelt D, Grüneberg U, Lohmann H, Schneider-Hohendorf T, Schulte-Mecklenbeck A, Gross CC, Meuth SG, Wiendl H, Husstedt IW.

Ann Clin Transl Neurol. 2015 Sep;2(9):906-19. doi: 10.1002/acn3.227. Epub 2015 Aug 18.

22.

Trafficking of lymphocytes into the CNS.

Schwab N, Schneider-Hohendorf T, Wiendl H.

Oncotarget. 2015 Jul 20;6(20):17863-4. No abstract available.

23.

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Klotz L, Grützke B, Eveslage M, Deppe M, Gross CC, Kirstein L, Posevitz-Fejfar A, Schneider-Hohendorf T, Schwab N, Meuth SG, Wiendl H.

BMC Neurol. 2015 Jun 23;15:96. doi: 10.1186/s12883-015-0354-9.

24.

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.

Schwab N, Schneider-Hohendorf T, Wiendl H.

Int Immunol. 2015 Jan;27(1):47-53. doi: 10.1093/intimm/dxu096. Epub 2014 Oct 17. Review.

PMID:
25326459
25.

[Prognostic and predictively relevant factors for multiple sclerosis].

Tackenberg B, Schneider-Hohendorf T, Müller A, Schodrowski J, Wiendl H.

Nervenarzt. 2014 Oct;85(10):1255-62. doi: 10.1007/s00115-014-4062-2. Review. German.

PMID:
25252736
26.

VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.

Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, Gross CC, Flanagan K, Sorokin L, Vestweber D, Zarbock A, Schwab N, Wiendl H.

J Exp Med. 2014 Aug 25;211(9):1833-46. doi: 10.1084/jem.20140540. Epub 2014 Aug 18.

27.

Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity.

Breuer J, Schwab N, Schneider-Hohendorf T, Marziniak M, Mohan H, Bhatia U, Gross CC, Clausen BE, Weishaupt C, Luger TA, Meuth SG, Loser K, Wiendl H.

Ann Neurol. 2014 May;75(5):739-58. doi: 10.1002/ana.24165. Epub 2014 May 13.

PMID:
24771567
28.

Specific loss of cellular L-selectin on CD4(+) T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection.

Schneider-Hohendorf T, Philipp K, Husstedt IW, Wiendl H, Schwab N.

AIDS. 2014 Mar 13;28(5):793-5. doi: 10.1097/QAD.0000000000000201.

PMID:
24445368
29.

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H.

Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7.

PMID:
23925765
30.

Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.

Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, Staugaitis SM, Welch W, Jilek S, Du Pasquier RA, Brück W, Toyka KV, Ransohoff RM, Wiendl H.

Neurology. 2012 Feb 14;78(7):458-67; discussion 465. doi: 10.1212/WNL.0b013e3182478d4b. Epub 2012 Feb 1.

31.

CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy.

Schneider-Hohendorf T, Schwab N, Uçeyler N, Göbel K, Sommer C, Wiendl H.

Neurology. 2012 Feb 7;78(6):402-8. doi: 10.1212/WNL.0b013e318245d250. Epub 2012 Jan 11.

PMID:
22238416
32.

Immunological and clinical consequences of treating a patient with natalizumab.

Schwab N, Höhn KG, Schneider-Hohendorf T, Metz I, Stenner MP, Jilek S, Du Pasquier RA, Gold R, Meuth SG, Ransohoff RM, Brück W, Wiendl H.

Mult Scler. 2012 Mar;18(3):335-44. doi: 10.1177/1352458511421919. Epub 2011 Sep 9.

PMID:
21908480
33.

Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels.

Bobak N, Bittner S, Andronic J, Hartmann S, Mühlpfordt F, Schneider-Hohendorf T, Wolf K, Schmelter C, Göbel K, Meuth P, Zimmermann H, Döring F, Wischmeyer E, Budde T, Wiendl H, Meuth SG, Sukhorukov VL.

Biochim Biophys Acta. 2011 Aug;1808(8):2036-44. doi: 10.1016/j.bbamem.2011.04.013. Epub 2011 May 5.

34.

Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking.

Göbel K, Pankratz S, Schneider-Hohendorf T, Bittner S, Schuhmann MK, Langer HF, Stoll G, Wiendl H, Kleinschnitz C, Meuth SG.

J Autoimmun. 2011 Mar;36(2):106-14. doi: 10.1016/j.jaut.2010.11.004. Epub 2011 Jan 8.

PMID:
21216565
35.

Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis.

Schneider-Hohendorf T, Stenner MP, Weidenfeller C, Zozulya AL, Simon OJ, Schwab N, Wiendl H.

Eur J Immunol. 2010 Dec;40(12):3581-90. doi: 10.1002/eji.201040558.

36.

Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis.

Doerck S, Göbel K, Weise G, Schneider-Hohendorf T, Reinhardt M, Hauff P, Schwab N, Linker R, Mäurer M, Meuth SG, Wiendl H.

PLoS One. 2010 Nov 15;5(11):e15478. doi: 10.1371/journal.pone.0015478.

37.

Effects on capacitance by overexpression of membrane proteins.

Zimmermann D, Zhou A, Kiesel M, Feldbauer K, Terpitz U, Haase W, Schneider-Hohendorf T, Bamberg E, Sukhorukov VL.

Biochem Biophys Res Commun. 2008 May 16;369(4):1022-6. doi: 10.1016/j.bbrc.2008.02.153. Epub 2008 Mar 10.

PMID:
18331832

Supplemental Content

Loading ...
Support Center